Austrianova rolls out cell banking and fill finish services

By Gareth Macdonald contact

- Last updated on GMT

Austrianova facility in Bangkok
Austrianova facility in Bangkok

Related tags: Cancer

Austrianova has launched cell banking and fill finish services for cell therapy developers at its facility in Singapore.

The new offering– called GMP4Cells – will include the production of master cell banks and working cell banks for products in Phase I and II clinical trials.

The fill finish offering is also intended to support research rather than commercial supply.

CEO Walter Ginsburg said cell banking is a logical addition to Austrianova’s core cell encapsulation business and suggested the new offering is particularly suited to smaller developers.

These services should allow start-up companies and academic based cell products, vaccines to enter clinical trials in a quality assured manner but at lower cost than other, more conventional, cell banking companies offer​.”

The launch of the new services and expansion of the recently established Singapore facility follows a year after Austrianova set up a GMP manufacturing facility in Bangkok, Thailand for its encapsulation service.

Pancreatic cancer cell therapy

The Bangkok facility was set up in collaboration with Austrianova’s partner Nuvilex, a cancer and diabetes-focused clinical-stage biotechnology company that is now known as PharmaCyte Biotech.

In addition to being the regional base for Austrianova’s cell encapsulation business, the facility is also where cells used by PharmaCyte’s developmental pancreatic cancer treatment are prepared and shipped to trial sites.

The treatment is based on ifosfamide, which is a widely-used chemotherapeutic agent that prevents DNA replication in cancerous cells. The drug‘s therapeutic properties are triggered by a liver enzyme called cytochrome P450 that converts the prodrug into its active form.

Ifosfamide has demonstrated significant efficacy against pancreatic cancer. However, the doses required to achieve this are associated with significant side effects.

PharmaCyte’s focus is reducing these side effects by encapsulate combinations of the Ifosfamide prodrug with liver cells that have been modified to a large number of express cytochrome P450 enzymes. 

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us

Products

View more

Webinars